<DOC>
	<DOC>NCT02097251</DOC>
	<brief_summary>Emergency access granted to treat a single patient with advanced Mucopolysaccharidosis Type 7 with UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy via IV administration every other week (QOW) for up to 144 weeks.</brief_summary>
	<brief_title>An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<criteria>1 specific patient Confirmed diagnosis of MPS 7 based on leukocyte or fibroblast glucuronidase enzyme assay or genetic testing confirming diagnosis. Written informed consent of parent(s) or legal guardian(s)</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mucopolysaccharidosis Type 7</keyword>
	<keyword>Sly syndrome</keyword>
	<keyword>UX003</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>rare disease</keyword>
	<keyword>Lysosomal Storage Disease</keyword>
	<keyword>metabolic disorder</keyword>
</DOC>